Lab Information
Talat Bessissow (MD/MSc)
InvestigatorClinical Research Unit
Department of Medicine (McGill)
Research Profile
Keywords
Crohn's disease • ulcerative colitis • mucosal healing • neoplasia • pathogenesisResearch Interests
My research focuses on the role of mucosal healing in the treatment of inflammatory bowel diseases. I am also looking at identifying factor that predict disease relapse.Team Members
| Name | Position |
|---|
Latest Publications
- van Lierop, L. M. A., Dang, R., Bessissow, T., Narula, N., Ramsay, T., Greenstreet, P., Hoentjen, F. & Murthy, S. K. (2026). Practices and perceptions of advanced endoscopic imaging techniques for colorectal neoplasia detection in patients with inflammatory bowel disease: report of a survey among Canadian inflammatory bowel disease specialists. iGIE : innovation, investigation and insights, vol. 5, p. 173-181.e6.
- Nadeem, H., Lakatos, P. L., Hagh-Doust, H., Wyse, J. M., Nadeem, H. & Bessissow, T. (2026). Successful Treatment of Refractory Pruritus in Primary Sclerosing Cholangitis with Upadacitinib: A Case Report. Case reports in gastroenterology, vol. 20, p. 157-166.
- Alsaeid, M., Abu Hawi, O., Bessissow, T. & Lakatos, P. L. (2026). IBD and Immune-Mediated Inflammatory Diseases: What Is the Optimal Management?. Journal of clinical medicine, vol. 15.
- Dubé, L.-R., Sorin, M., Allez, M., Afif, W., Bitton, A., Lakatos, P. L., Wild, G., Magro, F., Patel, A., Guardiola, J. & Bessissow, T. (2026). The Association of Faecal Calprotectin Measurements With Endo-Histological Remission in Ulcerative Colitis: A Pooled Analysis. Alimentary pharmacology & therapeutics.
- Ngew, E., Stobbs, J. A., Bessissow, T. & George, S. (2026). A modified synchrotron X-ray phase-contrast micro-CT workflow for non-destructive 3D imaging of intestinal biopsies. Talanta, vol. 309, p. 130019.
- Aboulhamid, N., Zoughlami, A., Evaristo, G. & Bessissow, T. (2026). Rare Rectal Involvement of Metastatic Appendiceal Adenocarcinoma Mimicking Primary Rectal Cancer. ACG case reports journal, vol. 13, p. e02045.
- Jairath, V., Bessissow, T., Glass, J., Braun, M., Gibble, T. H., Movsessian, T., Atkinson, C., Ellis, H., Dewar, T. & Panaccione, R. (2026). Communicating Needs and Features of IBD Experiences study: Canadian individuals and healthcare professional perceptions of the experience and impact of symptoms of moderate-to-severe ulcerative colitis and Crohn's disease. Journal of the Canadian Association of Gastroenterology, vol. 9, p. 38-48.
- Kritzinger, J., Candel, I., Kotrri, G., Nadeem, H., Afif, W., Bitton, A., Wild, G., Bessissow, T. & Lakatos, P. L. (2025). Clinical outcomes and drug sustainability after non-medical switch from ustekinumab originator to biosimilars in inflammatory bowel disease. World journal of gastroenterology, vol. 31, p. 114355.
- Isnard, S., Berini, C. A., Parvathy, S. N., Feng, H., Aiyana, O., Royston, L., Mabanga, T., Lakatos, P. L., Bessissow, T., Klein, M. B., Lebouché, B., Costiniuk, C. T., Routy, B., Silverman, M. S. & Routy, J.-P. (2025). Fecal microbiota transplantation to reduce immune activation in ART-treated people with HIV with low CD4/CD8 ratio: protocol for the single-blind, randomized, placebo-controlled Gutsy study (CIHR/CTN PT038). Trials, vol. 27, p. 52.
- Hagh-Doust, H., Nadeem, H., Bessissow, T. & Lakatos, P. L. (2025). New-Onset Ulcerative Colitis after Secukinumab Initiation: A Case Report. Case reports in gastroenterology, vol. 19, p. 726-730.
See also
